CD19 and B-cell non-Hodgkin lymphoma: To confirm that rhIL-7-hyFc enhances CAR T cell anti-tumor activity in an immunocompetent host, we transitioned to using a B cell lymphoma cell line, A20, that expresses murine CD19, engrafted into Balb/c mice.